Long-term haloperidol treatment (but not risperidone) enhances addiction-related behaviors in mice: Role of dopamine D2 receptors

Addiction Biology

Volumn 14, Issue 3, 2009, Pages 283-293

  Carvalho, Rita C ^a   Fukushiro, Daniela F ^a   Helfer, Daniel C ^a   Callegaro Filho, Donato ^a   Trombin, Thaís F ^a   Zanlorenci, Lineane H F ^a   Sanday, Leandro ^a   Silva, Regina H ^b   Frussa Filho, Roberto ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO NORTE   (Brazil)

Author keywords

Dopamine D2 receptors; Dopaminergic supersensitivity; Haloperidol; Hyperlocomotion; Risperidone; Stereotypy

Indexed keywords

AMPHETAMINE; APOMORPHINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; QUINPIROLE; RISPERIDONE;

ADDICTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG EFFECT; FEMALE; LOCOMOTION; LONG TERM CARE; MESOLIMBIC DOPAMINERGIC SYSTEM; MOUSE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PRIORITY JOURNAL; STEREOTYPY; SUPERSENSITIVITY; TREATMENT RESPONSE; WITHDRAWAL SYNDROME;

AMPHETAMINE-RELATED DISORDERS; ANIMALS; ANTIPSYCHOTIC AGENTS; APOMORPHINE; CORPUS STRIATUM; DOPAMINE AGONISTS; FEMALE; HALOPERIDOL; LIMBIC SYSTEM; LONG-TERM CARE; MESENCEPHALON; MICE; MOTOR ACTIVITY; NEURAL PATHWAYS; RECEPTORS, DOPAMINE D2; RISPERIDONE; STEREOTYPED BEHAVIOR; SUBSTANCE WITHDRAWAL SYNDROME; SUBSTANTIA NIGRA; UP-REGULATION;

EID: 67650468388     PISSN: 13556215     EISSN: 13691600     Source Type: Journal    
DOI: 10.1111/j.1369-1600.2008.00145.x     Document Type: Article

References (69)

1. Abílio VC, Freitas FM, Dolnikoff MS, Castrucci AM, Frussa-Filho R (1999) Effects of continuous exposure to light on behavioral dopaminergic supersensitivity. Biol Psychiatry 42 : 1622 1629. (Pubitemid 29292837)
2. Abílio VC, Vera JAR Jr., Ferreira SM, Duarte RM, Martins CR, Torres-Leite D, Ribeiro R de A, Frussa-Filho R (2003) Effects of melatonin on behavioral dopaminergic supersensitivity. Life Sci 72 : 3003 3015. (Pubitemid 36432057)
3. Ahlenius S, Hillegaart V, Thorell G, Magnusson O, Fowler CJ (1987) Supression of exploratory locomotor activity and increase in dopamine turnover following the local application of cis-flupenthixol into limbic projection areas of the rat striatum. Brain Res 420 : 131 138. (Pubitemid 17006937)
4. Andersen ML, Perry JC, Tufik S (2005) Acute cocaine effects in paradoxical sleep deprived male rats. Prog Neuropsychopharmacol Biol Psychiatry 29 : 245 251. (Pubitemid 40202910)
5. Arnt J (1995) Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of D-amphetamine. Eur J Pharmacol 283 : 55 62.
6. Bellot RG, Camarini R, Vital MABF, Palermo-Neto J, Leyton V, Frussa-Filho R (1996) Monosialoganglioside attenuates the excitatory and behavioural sensitization effects of ethanol. Eur J Pharmacol 313 : 175 179. (Pubitemid 26345977)
7. Bernardi MM, De Souza H, Palermo Neto J (1981) Effects of single and long-term haloperidol administration on open field behavior of rats. Psychopharmacology (Berl) 73 : 171 175. (Pubitemid 11150294)
8. Bernardi MM, Palermo-Neto J (1979) Effects of abrupt and gradual withdrawal from long-term haloperidol treatment on open field behavior of rats. Psychopharmacology (Berl) 65 : 247 250. (Pubitemid 10194750)
9. Burt DR, Creese I, Snyder SH (1977) Antischizophrenic drugs: chronic treatment elevates dopaminergic receptor in brain. Science 196 : 326 327.
10. Cadoni C, Solinas M, Di Chiara G (2000) Psychostimulant sensitization: differential changes in accumbal shell and core dopamine. Eur J Pharmacol 388 : 69 76. (Pubitemid 30066438)
11. Caley CF, Cooper CK (2002) Ziprasidone: the fifth atypical antipsychotic. Ann Pharmacother 36 : 839 851. (Pubitemid 34517416)
12. Calzavara MB, Andersen ML, Fukushiro DF, Lopez GB, Abílio VC, Tufik S, Frussa-Filho R (2008) Sleep rebound attenuates context-dependent behavioural sensitization induced by amphetamine. Prog Neuropsychopharmacol Biol Psychiatry 32 : 1277 1282.
13. Casey DE (1995) Tardive dyskinesia - pathophysiology. In : Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress, pp. 1497 1502. New York : Raven Press.
14. Chinen CC, Faria RR, Frussa-Filho R (2006) Characterization of the rapid-onset type of behavioral sensitization to amphetamine in mice: role of drug-environment conditioning. Neuropsychopharmacology 31 : 151 159. (Pubitemid 43250950)
15. Chouinard G, Jones BD (1980) Neuroleptic-induced supersensitivity psychosis: clinical and pharmacological characteristics. Am J Psychiatry 137 : 16 21. (Pubitemid 10130757)
16. Chouinard G, Jones BD, Annable L (1978) Neuroleptic-induced supersensitivity psychosis. Am J Psychiatry 135 : 1409 1410. (Pubitemid 9016545)
17. Conceição IM, Frussa-Filho R (1996) Effects of microgram doses of haloperidol on open-field behavior in mice. Pharmacol Biochem Behav 53 : 833 838. (Pubitemid 26112949)
18. Costa FG, Frussa-Filho R, Felício LF (2001) The neurotensin receptor antagonist, SR48692, attenuates the expression of amphetamine-induced behavioural sensitization in mice. Eur J Pharmacol 428 : 97 103. (Pubitemid 32971762)
19. Creese I, Iversen SD (1975) Behavioural sequelae of dopaminergic degeneration: postsynaptic supersensitivity? Psychopharmacol Bull 11 : 12 13.
20. Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M (1999) Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology 20 : 491 505. (Pubitemid 29123876)
21. Delfs JM, Schreiber L, Kelley AE (1990) Microinjection of cocaine into the nucleus accumbens elicits locomotor activation in the rat. J Neurosci 10 : 303 310. (Pubitemid 20059266)
22. Eilam D, Szechtman H (1989) Biphasic effect of D2 agonist quinpirole on locomotion and movements. Eur J Pharmacol 161 : 151 157. (Pubitemid 19080497)
23. Everitt BJ, Robbins TW (2005) Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nat Neurosci 8 : 1481 1489. Review. (Pubitemid 41573659)
24. Fleminger S, Rupniak NMJ, Hall MD, Jenner P, Marsden CD (1983) Changes in apomorphine-induced stereotypy as a result of subacute neuroleptic treatment correlates with increased D-2 receptors, but not increases in D-1 receptors. Biochem Pharmacol 32 : 2921 2927.
25. Frussa-Filho R, Gonçalves MTM, Andersen ML, Araújo NP, Chinen CC, Tufik S (2004) Paradoxical sleep deprivation potentiates amphetamine-induced behavioural sensitization by increasing its conditioned component. Brain Res 1003 : 188 193. (Pubitemid 38317100)
26. Fukushiro DF, Alvarez J N, Tatsu JA, de Castro JP, Chinen CC, Frussa-Filho R (2007) Haloperidol (but not ziprasidone) withdrawal enhances cocaine-induced locomotor activation and conditioned place preference in mice. Prog Neuropsychopharmacol Biol Psychiatry 31 : 867 872. (Pubitemid 46661967)
27. Fukushiro DF, Carvalho R C, Ricardo VP, Alvarez J N, Ribeiro LT, Frussa-Filho R (2008) Haloperidol (but not ziprasidone) withdrawal potentiates sensitization to the hyperlocomotor effect of cocaine in mice. Brain Res Bull 77 : 124 128.
28. Gianutsos G, Drawbaugh RB, Hynes MD, Lal H (1974) Behavioral evidence for dopaminergic supersensitivity after chronic haloperidol. Life Sci 14 : 887 898.
29. Hartfield AW, Moore NA, Clifton PG (2006) Effects of atypical antipsychotic drugs on intralipid intake and cocaine-induced hyperactivity in rats. Neuropsychopharmacology 31 : 1938 1945. (Pubitemid 44246340)
30. Jones DN, Bowen WD, Portoghese PS, Holtzman SG (1993) Delta-opioid receptor antagonists attenuate motor activity induced by amphetamine but not cocaine. Eur J Pharmacol 249 : 167 177.
31. Kelly PH, Iversen SD (1976) Selective 6OHDA-induced destruction of mesolimbic dopamine neurons: abolition of psychostimulant-induced locomotor activity in rats. Eur J Pharmacol 40 : 45 56.
32. Kelly PH, Seviour PW, Iversen SD (1975) Amphetamine and apomorphine responses in the rat following 6-OHDA lesion of the nucleus accumbens, septi and corpus striatum. Brain Res 94 : 507 522.
33. Klawans HL (1973) The pharmacology of tardive dyskinesia. Am J Psych 130 : 82 86.
34. Leduc PA, Mittleman G (1993) Interactions between chronic haloperidol treatment and cocaine in rats: an animal model of intermittent cocaine use in neuroleptic treated populations. Psychopharmacology 110 : 427 436. (Pubitemid 23074566)
35. LeDuc PA, Mittleman G (1995) Schizophrenia and psychostimulant abuse: a review and re-analysis of clinical evidence. Psychopharmacology (Berl) 121 : 407 427.
36. Lomanowska A, Gormley S, Szechtman H (2004) Presynaptic stimulation and development of locomotor sensitization to the dopamine agonist quinpirole. Pharmacol Biochem Behav 77 : 617 622. (Pubitemid 38296823)
37. Meltzer HY, Matsubara S, Lee JC (1989) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D1, D2 and 5HT2 pKi values. J Pharmacol Exp Ther 251 : 238 246.
38. Muller P, Seeman P (1978) Dopaminergic supersensitivity after neuroleptics: time course and specificity. Psychopharmacology 60 : 1 11. (Pubitemid 9106035)
39. Nemeroff CB, Lieberman JA, Weiden PJ, Harvey PD, Newcomer JW, Schatzberg AF, Kilts CD, Daniel DG (2005) From clinical research to clinical practice: a 4-year review of ziprasidone. CNS Spectr 10 : s1 20.
40. Palermo-Neto J (1982) Supersensitivity, drug withdrawal and open-field behavior. Psychopharmacol Bull 18 : 11 12.
41. Palermo-Neto J, Frussa-Filho R (2001) Behavioral models of tardive dyskinesia in rodents. A cronological overview. In : Bolis CL, Pani L, Licinio J, eds. Dopaminergic Systems: Evolution from Biology to Clinical Aspects, pp. 61 82. Lippincott, Williams & Wilkins, USA : Philadelphia.
42. Perry JC, Vital MABF, Frussa-Filho R, Tufik S, Palermo-Neto J (2004) Monosialoganglioside (GM1) attenuates the behavioural effects of long-term haloperidol administration in supersensitive rats. Eur Neuropsychopharmacol 14 : 127 133. (Pubitemid 38175430)
43. Phillips TJ, Roberts AJ, Lessov CN (1997) Behavioral sensitization to ethanol: genetics and the effects of stress. Pharmacol Biochem Behav 57 : 487 493. (Pubitemid 27296760)
44. Pijnenburg AJ, Honig WM, Van Rossum JM (1975) Inhibition of d-amphetamine-induced locomotor activity by injection of haloperidol into the nucleus accumbens of the rat. Psychopharmacologia 41 : 87 95.
45. Potvin S, Stip E, Roy JY (2003) Clozapine, quetiapine and olanzapine among addicted schizophrenic patients: towards testable hypotheses. Int Clin Psychopharmacol 18 : 121 132. (Pubitemid 36575481)
46. Queiroz CMT, Alcântara FG, Yagüe AML, Bibancos T, Frussa-Filho R (2002) Acute buspirone abolishes the expression of behavioral dopaminergic supersensitivity in mice. Braz J Med Biol Res 35 : 237 242. (Pubitemid 34229069)
47. Queiroz CMT, Frussa-Filho R (1997) Effects of buspirone on dopaminergic supersensitivity. Life Sci 61 : 371 382. (Pubitemid 27305574)
48. Richtand NM, Woods SC, Berger SP, Strakowski SM (2001) D3 dopamine receptor, behavioral sensitization, and psychosis. Neurosci Biobehav Rev 25 : 427 443. (Pubitemid 32879299)
49. Robinson TE, Berridge KC (1993) The neural basis of drug craving: an incentive-sensitization theory of addiction (Review). Brain Res Rev 18 : 247 291. (Pubitemid 23219500)
50. Robinson TE, Berridge KC (2000) The psychology and neurobiology of addiction: an incentive-sensitization view. Addiction 95 (Suppl 2 S91 117.
51. Robinson TE, Berridge KC (2001) Incentive-sensitization and addiction. Addiction 96 : 103 114. (Pubitemid 32099343)
52. Saller CF, Czupryna MJ, Salama AI (1990) 5-HT2 receptors blockade by ICI 169369 and other 5-HT2 antagonist modulates the effects of D-2 dopamine receptor blockade. J Pharmacol Exp Ther 253 : 1162 1170.
53. Schmidt AW, Lebel LA, Howard HR Jr., Zorn SH (2001) Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol 425 : 197 201. (Pubitemid 32770067)
54. Schotte A, Janssen PFM, Fommeren W, Luyten WHML, Gompel PV, Lesage AS, De Loore K, Leysen JE (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 124 : 57 73. (Pubitemid 26112775)
55. Setler P, Sarau H, Mckenzie G (1976) Differential attenuation of some effects of haloperidol in rats given scopolamine. Eur J Pharmacol 39 : 117 126.
56. Shayegan DK, Stahl SM (2004) Atypical antipsychotics: matching receptor profile to individual patient's clinical profile. CNS Spectr 9 (10 Suppl 11 6 14. (Pubitemid 39473434)
57. Smelson DA, Losonczy MF, Davis CW, Kaune M, Williams J, Ziedonis D (2002) Risperidone decreases craving and relapses in individuals with schizophrenia and cocaine dependence. Can J Psychiatry 47 : 671 675. (Pubitemid 35192034)
58. Stahl SM, Shayegan DK (2003) The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry 64 (Suppl 19 6 12.
59. Tarazi FI, Yeghiayan SK, Baldessarini RJ, Kula NS, Neumeyer JL (1997) Long-term effects of s(+) N-propylnorapomorphine compared with typical and atypical antipsychotics: differential increases of cerebrocortical D2-like and striatolimbic D4-like dopamine receptor. Neuropsychopharmacology 17 : 186 196. (Pubitemid 27365959)
60. Tarazi FI, Zhang K, Baldessarini RJ (2001) Long-term effects of olanzapine, risperidone and quetiapine on dopamine receptor types in regions of rat brain: implications for antipsychotic drug treatment. J Pharmacol Exp Ther 297 : 711 717. (Pubitemid 32378004)
61. Tsuang JW, Stephen MD, Han AM, Winnie H (2002b) Olanzapine treatment for patients with schizophrenia and cocaine abuse. J Clin Psychopharmacol 63 : 1100 1101.
62. Tsuang JW, Eckman T, Marder S, Tucker D (2002a) Can risperidone reduce cocaine use in substance abusing schizophrenic patients? J Clin Psychopharmacol 22 : 629 630. (Pubitemid 35416793)
63. Tzschentke TM, Schmidt WJ (2000) Differential effects of discrete subarea-specific lesions of the rat medial prefrontal cortex on amphetamine- and cocaine-induced behavioural sensitization. Cereb Cortex 10 : 488 498. (Pubitemid 30318456)
64. van Campenhout N, De Haes P, Meert TF (1999) Inability of antipsychotics to antagonize the cueing properties of cocaine in rats. Pharmacol Biochem Behav 64 : 435 438. (Pubitemid 29438635)
65. Vanderschuren LJ, Everitt BJ (2005) Behavioral and neural mechanisms of compulsive drug seeking. Eur J Pharmacol 526 : 77 88. Review. (Pubitemid 41744107)
66. Vital MABF, Flório JC, Frussa-Filho R, De Lucia R, Tufik S, Palermo-Neto J (1998) Effects of haloperidol and GMI ganglioside treatment on striatal D2 receptor binding and dopamine turnover. Life Sci 62 : 1161 1169. (Pubitemid 28153475)
67. Vital MABF, Frussa-Filho R, Palermo-Neto J (1995) Effects of monosialoganglioside GMI on dopaminergic supersensitivity. Life Sci 56 : 2299 2307.
68. Wise RA (1988) The neurobiology of craving: implications for the understanding and treatment of addiction (review). J Abnorm Psychol 97 : 118 132. (Pubitemid 18235611)
69. Wolf ME, White FJ, Hu XT (1994) MK-801 prevents alterations in the mesoaccumbens dopamine system associated with behavioral sensitization to amphetamine. J Neurosci 14 (Part 2 1735 1745. (Pubitemid 24080021)